Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 4
Submit an article Journal homepage
362
Views
8
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia

Vishal DhereDepartment of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA; View further author information
,
Scott EdelmanDepartment of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA; View further author information
,
Edmund K. WallerDepartment of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA, USA; View further author information
,
Amelia LangstonDepartment of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA, USA; View further author information
,
Michael GraiserDepartment of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA, USA; View further author information
,
Erin C. ConnollyDepartment of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA; View further author information
,
Jeffrey M. SwitchenkoDepartment of Biostatistics and Bioinformatics, Winship Cancer Institute at Emory University, Atlanta, GA, USAView further author information
,
Natia EsiashviliDepartment of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA; View further author information
&
Mohammad K. KhanDepartment of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA; Correspondence[email protected]
View further author information
 show all
Pages 837-843 | Received 18 Apr 2017, Accepted 19 Jul 2017, Published online: 07 Aug 2017

References

  • McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol. 2009;5:957–969.
  • Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347–1353.
  • Bacigalupo A. Hematopoietic stem cell transplants after reduced intensity conditioning regime (RI-HSCT): report of a workshop of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2000;25:803–805.
  • Carella AM, Champlin R, Slavin S, et al. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant. 2000;25:345–350.
  • Wahid SFA, Ismail NA, Mohd-Idris MR, et al. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis. Stem Cells Dev. 2014;23:2535–2552.
  • Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006;20:322–328.
  • Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154–1161.
  • Baron F, Labopin M, Peniket A, et al. Reduced-intensity condition in myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromesg with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2015;121:1048–1055.
  • Copelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122:3863–3870.
  • Shimoni A, Hardan I, Shem-Tov N, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia. 2007;21:2109–2116.
  • Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
  • Therneau T. A package for survival analysis in S version 2.38. 2015.
  • Gray RJ. cmprsk: Subdistribution analysis of competing risks, 2014.
  • Nagler A, Labopin M, Shimoni A, et al. Intravenous busulfan-based conditioning prior to allogeneic stem cell transplantation in adults patients with AML – an ALWP-EBMT survey. Blood. 2007;110:1995.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.